-
Discontinuation of anticoagulation 3-6 months after successful atrial fibrillation ablation is reasonable in low-risk patients.
-
Angiotensin-converting enzyme (ACE) inhibitors have been shown to reduce mortality and myocardial infarction (MI) in patients with heart failure due to reduced left ventricular (LV) systolic function.
-
Seybolt and colleagues performed a retrospective analysis of refugees seen as part of a 2-visit health evaluation at Boston Medical Center from October 1998 through May 2002.
-
At the University of Pittsburgh Medical Center, laboratory-based surveillance of coagulase-negative staphylococci found that 4% were linezolid resistant. MIC's to linezolid were generally > 256 ug/mL; the isolates were all susceptible to vancomycin and daptomycin.
-
This paper presents the results of a retrospective cohort analysis from the Mayo Clinic of 79 patients with bacterial spine infection who underwent baseline and follow-up imaging studies with MRI.
-
Within the past few months, gatifloxacin (Tequin®) has received some attention in the medical community due to reports of serious hypoglycemia and hyperglycemia.
-
ACE inhibitors are associated with a reduced risk of ruptured abdominal aortic aneurysm, unlike other antihypertensive agents. Randomised trials of ACE inhibitors for prevention of aortic rupture might be warranted.
-
The 2006 guidelines for the management of patients with atrial fibrillation clarify previous recommendations for anticoagulation to prevent other thromboembolic events.
-
In ACS patients without persistent ST-segment elevation, there is a strong, consistent, temporal, and dose-related association between bleeding and death.
-
A team from UCSF recently reviewed company documents that were entered into the public record as a result of litigation over the promotion of gabapentin (Neurontin) between 1994 and 1998.